Nevirapin Heumann (Nevirapine)

Nevirapine binds to a non‑nucleoside site on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that blocks the enzyme’s activity. This prevents the conversion of viral RNA into DNA, halting the replication cycle of the virus.

The dosage of nevirapine is individualized by the prescribing clinician based on factors such as the patient’s treatment history, weight, liver function, and co‑medications. Only a qualified health professional should determine the appropriate regimen.

Safety data for nevirapine in pregnancy and lactation are limited. The drug should only be used if the potential benefits outweigh the risks, and the decision must be made by a qualified health‑care provider after careful assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both nevirapine and efavirenz belong to the NNRTI class and are used in combination HIV regimens. Nevirapine is often chosen for its lower central nervous system side‑effect profile, while efavirenz may have a higher risk of neuropsychiatric events. The choice depends on patient tolerance, drug‑interaction potential and clinical guidelines.

Nevirapin Heumann should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Nevirapin Heumann is taken orally, usually as a tablet swallowed whole with water. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber to maintain consistent drug levels.

The most serious adverse reactions include severe skin reactions such as Stevens‑Johnson syndrome, hepatic toxicity that may lead to liver failure, and hypersensitivity syndromes with fever and organ involvement. Prompt medical attention is required if any of these symptoms develop.

Nevirapin Heumann is contraindicated in individuals with a known hypersensitivity to nevirapine or any component of the formulation, and in patients with severe hepatic impairment. Caution is also advised for those with a history of severe rash or liver disease.